Search Cancer Clinical Trials

The Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
Protocol # 20-211

Status

Recruiting

Description

This is a dose escalation study and will be the first to administer SY-5609 alone to humans with select advanced solid tumors and in combination with Fulvestrant to patients with HR positive, HER2-negative breast cancer.

Condition

  • Advanced Solid Tumor
  • Breast Cancer

Interventions

  • SY-5609
  • Fulvestrant

Phase

Phase 1

Study Type

Interventional

Further Study Details

Primary Outcome:

  • Single Agent Dose Limiting Toxicity
  • Single Agent Incidence of Adverse Events
  • Changes in Hematologic Lab Values from Baseline
  • Changes in Chemistry Lab Values from Baseline
  • Changes in Coagulation Values from Baseline
  • Changes in Urinalysis Values from Baseline
  • Changes in Electrocardiograms (ECGs)
  • Body Temperature
  • Blood Pressure
  • Heart Rate
  • Respiratory Rate

Enrollment

80

Study Start Date

January 23, 2020

Eligibility

  • Gender:     All
  • Minimum age:     18 Years
  • Maximum age:     N/A
  • Healthy volunteers:     No

Sponsors

Syros Pharmaceuticals

Source

Syros Pharmaceuticals

Official title

A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors

Clinicaltrials.gov Identifier

NCT04247126

     

Source: Clinicaltrials.gov. Through our founding membership in the Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center, these clinical trials are conducted at the Massachusetts General Hospital Cancer Center and may be available at other partner institutions.